We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Normal Brain Electrical Activity Protects Nerves from Huntington's Disease Peptides

By LabMedica International staff writers
Posted on 02 Dec 2009
Print article
The normal level of brain electrical activity (normal synaptic activity) protects nerve cells from the affect of the toxic peptides that characterize Huntington's disease.

Huntington's disease is a neurodegenerative disorder caused by a mutation in the gene that encodes for the huntingtin (Htt) protein. The mutated gene adds from one to many dozens of extra glutamine molecules to Htt. Incomplete breakdown of the enlarged protein results in the buildup of toxic, misfolded peptides that destroy cells in the nervous system.

Working with a mouse model of Huntington's disease, investigators at the Burnham Institute for Medical Research (La Jolla, CA, USA) examined the part played by brain electrical activity on the interaction between nerve cells and toxic Htt peptides.

They reported in the November 15, 2009, online edition of the journal Nature Medicine that normal synaptic receptor activity made nerve cells more resistant to Htt peptides. In contrast, excessive extrasynaptic electrical activity contributed to increased nerve cell death.

Treatment of mice that had been transfected with Htt peptides with low doses of the drug memantine, which is used to treat Alzheimer's disease, was found to effectively protect the animals' nerve cells. This was due to the action of the drug in reducing excessive NMDA-type glutamate receptor activity (synaptic N-methyl-D-aspartate-type glutamate receptor activity), which prevented the expression of excessive extasynaptic activity. However, high-doses of memantine stimulated disease progression, as it also blocked lower level protective synaptic NMDA receptor activity.

"Chronic neurodegenerative diseases like Huntington's, Alzheimer's and Parkinson's are all related to protein misfolding," said senior author Dr. Stuart A. Lipton, professor of neurosciences at the Burnham Institute. "We show here, for the first time, that electrical activity controls protein folding, and if you have a drug that can adjust the electrical activity to the correct levels, you can protect against misfolding. Also, this verifies that appropriate electrical activity is protective, supporting the ‘use it or lose it theory' of brain activity at the molecular level. For example, this finding may explain why epidemiologists have found that "using" your brain by performing crossword puzzles and other games can stave off cognitive decline in diseases like Alzheimer's."

Related Links:
Burnham Institute for Medical Research


New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new ADLM guidance will help healthcare professionals navigate respiratory virus testing in a post-COVID world (Photo courtesy of 123RF)

New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections

Respiratory tract infections, predominantly caused by viral pathogens, are a common reason for healthcare visits. Accurate and swift diagnosis of these infections is essential for optimal patient management.... Read more

Molecular Diagnostics

view channel
Image: The HelioLiver Dx test has met the coprimary and secondary study endpoints in the CLiMB trial (Photo courtesy of Helio Genomics)

Blood-Based Test Outperforms Ultrasound in Early Liver Cancer Detection

Patients with liver cirrhosis and chronic hepatitis B are at a higher risk for developing hepatocellular carcinoma (HCC), the most prevalent type of liver cancer. The American Association for the Study... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The POC PCR test shortens time for STI test results (Photo courtesy of Visby Medical)

POC STI Test Shortens Time from ED Arrival to Test Results

In a 2024 sexually transmitted infections (STIs) surveillance report by the World Health Organization (WHO), over 2.5 million cases were recorded, alongside a rise in the inappropriate use of antibiotics... Read more

Industry

view channel
Image: For 46 years, Roche and Hitachi have collaborated to deliver innovative diagnostic solutions (Photo courtesy of Roche)

Roche and Hitachi High-Tech Extend 46-Year Partnership for Breakthroughs in Diagnostic Testing

Roche (Basel, Switzerland) and Hitachi High-Tech (Tokyo, Japan) have renewed their collaboration agreement, committing to a further 10 years of partnership. This extension brings together their long-standing... Read more
LGC Clinical Diagnostics